Metabolism, disposition, and kinetics of delta‐9‐tetrahydrocannabinol in men and women View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1983-09

AUTHORS

Monroe E Wall, Brian M Sadler, Dolores Brine, Harold Taylor, Mario Perez‐Reyes

ABSTRACT

A comparative study was done in women and men of the effects of delta 9-tetrahydrocannabinol (delta 9-THC), intravenously or orally, on dynamic activity, metabolism, excretion, and kinetics. In general no differences between the two sexes were observed. delta 9-THC is converted by microsomal hydroxylation to 11-hydroxy-delta 9-THC (11-OH-delta 9-THC), which is both a key intermediate for further metabolism to 11-nor-delta 9-THC-9-carboxylic acid (11-nor-acid) by liver alcohol-dehydrogenase enzymes and a potent psychoactive metabolite. Major differences in the ratio of the concentration of 11-OH-delta 9-THC to that of delta 9-THC in plasma were found after intravenous dosing (ratio 1:10 to 20) compared with oral administration (ratio 0.5 to 1:1). The final metabolic products are the 11-nor-acids and the related, more polar acids. Urinary excretion of delta 9-THC is restricted to acidic nonconjugated and conjugated metabolites. After 72 hr mean cumulative urinary excretion, noted for both routes and for both sexes, ranged from 13% to 17% of the total dose. After 72 hr the cumulative fecal excretion for both sexes after intravenous administration ranged from 25% to 30%; after oral administration the range was 48% to 53%. Metabolites were found in the feces in large concentration in the nonconjugated form; concentrations of 11-OH-delta 9-THC were particularly noteworthy. Kinetics of delta 9-THC and metabolites were much the same for female and male subjects. For delta 9-THC, terminal-phase t1/2s for both sexes, irrespective of the route, ranged from 25 to 36 hr. A comparison of the results for AUC/dose (delta 9-THC) after oral dosing with comparable data from intravenous administration indicated bioavailability of the order of 10% to 20% for both sexes. After intravenous delta 9-THC, large apparent volumes of distribution were noted (about 10 l/kg for both sexes). More... »

PAGES

352-363

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/clpt.1983.179

DOI

http://dx.doi.org/10.1038/clpt.1983.179

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040170860

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/6309462


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dronabinol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Parenteral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kinetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sex Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wall", 
        "givenName": "Monroe E", 
        "id": "sg:person.0107666412.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0107666412.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sadler", 
        "givenName": "Brian M", 
        "id": "sg:person.01053521033.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053521033.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brine", 
        "givenName": "Dolores", 
        "id": "sg:person.01305006065.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305006065.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Taylor", 
        "givenName": "Harold", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Perez\u2010Reyes", 
        "givenName": "Mario", 
        "id": "sg:person.01255166721.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255166721.72"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1983-09", 
    "datePublishedReg": "1983-09-01", 
    "description": "A comparative study was done in women and men of the effects of delta 9-tetrahydrocannabinol (delta 9-THC), intravenously or orally, on dynamic activity, metabolism, excretion, and kinetics. In general no differences between the two sexes were observed. delta 9-THC is converted by microsomal hydroxylation to 11-hydroxy-delta 9-THC (11-OH-delta 9-THC), which is both a key intermediate for further metabolism to 11-nor-delta 9-THC-9-carboxylic acid (11-nor-acid) by liver alcohol-dehydrogenase enzymes and a potent psychoactive metabolite. Major differences in the ratio of the concentration of 11-OH-delta 9-THC to that of delta 9-THC in plasma were found after intravenous dosing (ratio 1:10 to 20) compared with oral administration (ratio 0.5 to 1:1). The final metabolic products are the 11-nor-acids and the related, more polar acids. Urinary excretion of delta 9-THC is restricted to acidic nonconjugated and conjugated metabolites. After 72 hr mean cumulative urinary excretion, noted for both routes and for both sexes, ranged from 13% to 17% of the total dose. After 72 hr the cumulative fecal excretion for both sexes after intravenous administration ranged from 25% to 30%; after oral administration the range was 48% to 53%. Metabolites were found in the feces in large concentration in the nonconjugated form; concentrations of 11-OH-delta 9-THC were particularly noteworthy. Kinetics of delta 9-THC and metabolites were much the same for female and male subjects. For delta 9-THC, terminal-phase t1/2s for both sexes, irrespective of the route, ranged from 25 to 36 hr. A comparison of the results for AUC/dose (delta 9-THC) after oral dosing with comparable data from intravenous administration indicated bioavailability of the order of 10% to 20% for both sexes. After intravenous delta 9-THC, large apparent volumes of distribution were noted (about 10 l/kg for both sexes).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/clpt.1983.179", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "name": "Metabolism, disposition, and kinetics of delta\u20109\u2010tetrahydrocannabinol in men and women", 
    "pagination": "352-363", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "bf5c0f96181cba3b838312556115d9f6d5387774557af7ab3e65ec00cf96ce58"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "6309462"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0372741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/clpt.1983.179"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040170860"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/clpt.1983.179", 
      "https://app.dimensions.ai/details/publication/pub.1040170860"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000069.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://onlinelibrary.wiley.com/doi/10.1038/clpt.1983.179/abstract"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/clpt.1983.179'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/clpt.1983.179'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/clpt.1983.179'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/clpt.1983.179'


 

This table displays all metadata directly associated to this object as RDF triples.

139 TRIPLES      20 PREDICATES      38 URIs      30 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/clpt.1983.179 schema:about N09a2777f8cd24fab8b8ae11a3cdbe692
2 N0f8a1142cc7f46279860c4a27a3f6860
3 N4c10d3e1350e4cd2a02e0e1274fc67e0
4 N5a960e853ce94f6ba23a553b8d2cb26c
5 N5b8c0eb5c2b14296bf56a87a73627f83
6 Na714926446054c74a4297e1e3a1c74a2
7 Nbc4f7d506f4b41d0ac8553e154a3bd18
8 Nd1fba539efd44c2c8d5be9cc7fb546ec
9 Nf06c8badfe5c479686843cd57bcd5ad7
10 anzsrc-for:11
11 anzsrc-for:1115
12 schema:author N328e8a7dda1d46fca450eaa233f2a184
13 schema:datePublished 1983-09
14 schema:datePublishedReg 1983-09-01
15 schema:description A comparative study was done in women and men of the effects of delta 9-tetrahydrocannabinol (delta 9-THC), intravenously or orally, on dynamic activity, metabolism, excretion, and kinetics. In general no differences between the two sexes were observed. delta 9-THC is converted by microsomal hydroxylation to 11-hydroxy-delta 9-THC (11-OH-delta 9-THC), which is both a key intermediate for further metabolism to 11-nor-delta 9-THC-9-carboxylic acid (11-nor-acid) by liver alcohol-dehydrogenase enzymes and a potent psychoactive metabolite. Major differences in the ratio of the concentration of 11-OH-delta 9-THC to that of delta 9-THC in plasma were found after intravenous dosing (ratio 1:10 to 20) compared with oral administration (ratio 0.5 to 1:1). The final metabolic products are the 11-nor-acids and the related, more polar acids. Urinary excretion of delta 9-THC is restricted to acidic nonconjugated and conjugated metabolites. After 72 hr mean cumulative urinary excretion, noted for both routes and for both sexes, ranged from 13% to 17% of the total dose. After 72 hr the cumulative fecal excretion for both sexes after intravenous administration ranged from 25% to 30%; after oral administration the range was 48% to 53%. Metabolites were found in the feces in large concentration in the nonconjugated form; concentrations of 11-OH-delta 9-THC were particularly noteworthy. Kinetics of delta 9-THC and metabolites were much the same for female and male subjects. For delta 9-THC, terminal-phase t1/2s for both sexes, irrespective of the route, ranged from 25 to 36 hr. A comparison of the results for AUC/dose (delta 9-THC) after oral dosing with comparable data from intravenous administration indicated bioavailability of the order of 10% to 20% for both sexes. After intravenous delta 9-THC, large apparent volumes of distribution were noted (about 10 l/kg for both sexes).
16 schema:genre research_article
17 schema:inLanguage en
18 schema:isAccessibleForFree false
19 schema:isPartOf N1e52bfc1caec4a4a975eff07b4681b00
20 Nbe93e93f7f1e404eb2ca91118b9aada1
21 sg:journal.1017409
22 schema:name Metabolism, disposition, and kinetics of delta‐9‐tetrahydrocannabinol in men and women
23 schema:pagination 352-363
24 schema:productId N3631c247562d448c8ec8e4ecdfbac9f5
25 N65fa3bcaf0fc4964a71116fffb31e5d9
26 N72d16529d6424782a278e93ee6721515
27 Nc80be720ef0f47529604b37b20c55e21
28 Neb4cd6877ab34d3a8bef798aa70b3dbe
29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040170860
30 https://doi.org/10.1038/clpt.1983.179
31 schema:sdDatePublished 2019-04-10T18:37
32 schema:sdLicense https://scigraph.springernature.com/explorer/license/
33 schema:sdPublisher Nc0861c8adf424792b3ee8e6ac2f1f0de
34 schema:url http://onlinelibrary.wiley.com/doi/10.1038/clpt.1983.179/abstract
35 sgo:license sg:explorer/license/
36 sgo:sdDataset articles
37 rdf:type schema:ScholarlyArticle
38 N09a2777f8cd24fab8b8ae11a3cdbe692 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
39 schema:name Kinetics
40 rdf:type schema:DefinedTerm
41 N0c73d23472424e34a080607d6c57f77d schema:name University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill
42 rdf:type schema:Organization
43 N0e7547bf84744d5882e4ef24d82ba30a schema:affiliation Nfe1c19f5300f420da6d520d248870514
44 schema:familyName Taylor
45 schema:givenName Harold
46 rdf:type schema:Person
47 N0f8a1142cc7f46279860c4a27a3f6860 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
48 schema:name Female
49 rdf:type schema:DefinedTerm
50 N10226d64e7754217ac1c32a3d471603a rdf:first sg:person.01255166721.72
51 rdf:rest rdf:nil
52 N1e52bfc1caec4a4a975eff07b4681b00 schema:volumeNumber 34
53 rdf:type schema:PublicationVolume
54 N328e8a7dda1d46fca450eaa233f2a184 rdf:first sg:person.0107666412.52
55 rdf:rest N5a203107c6974770be5763b5d3b5aeef
56 N3631c247562d448c8ec8e4ecdfbac9f5 schema:name pubmed_id
57 schema:value 6309462
58 rdf:type schema:PropertyValue
59 N4050d22b7db544a2b5fb58849f947c0e schema:name University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill
60 rdf:type schema:Organization
61 N4c10d3e1350e4cd2a02e0e1274fc67e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Infusions, Parenteral
63 rdf:type schema:DefinedTerm
64 N5a203107c6974770be5763b5d3b5aeef rdf:first sg:person.01053521033.24
65 rdf:rest N9fbf946f811840419e92264f27fcd515
66 N5a960e853ce94f6ba23a553b8d2cb26c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Dronabinol
68 rdf:type schema:DefinedTerm
69 N5b8c0eb5c2b14296bf56a87a73627f83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Sex Factors
71 rdf:type schema:DefinedTerm
72 N65fa3bcaf0fc4964a71116fffb31e5d9 schema:name readcube_id
73 schema:value bf5c0f96181cba3b838312556115d9f6d5387774557af7ab3e65ec00cf96ce58
74 rdf:type schema:PropertyValue
75 N72d16529d6424782a278e93ee6721515 schema:name dimensions_id
76 schema:value pub.1040170860
77 rdf:type schema:PropertyValue
78 N7c0162bc950f45f987976848a6fb83e2 schema:name University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill
79 rdf:type schema:Organization
80 N9fbf946f811840419e92264f27fcd515 rdf:first sg:person.01305006065.32
81 rdf:rest Nf27e7797a8b0451ca2df3b6a417378dc
82 Na714926446054c74a4297e1e3a1c74a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Male
84 rdf:type schema:DefinedTerm
85 Nb853626a52504bbd8c89d9f931de3201 schema:name University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill
86 rdf:type schema:Organization
87 Nbc4f7d506f4b41d0ac8553e154a3bd18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Adult
89 rdf:type schema:DefinedTerm
90 Nbe93e93f7f1e404eb2ca91118b9aada1 schema:issueNumber 3
91 rdf:type schema:PublicationIssue
92 Nc0861c8adf424792b3ee8e6ac2f1f0de schema:name Springer Nature - SN SciGraph project
93 rdf:type schema:Organization
94 Nc80be720ef0f47529604b37b20c55e21 schema:name doi
95 schema:value 10.1038/clpt.1983.179
96 rdf:type schema:PropertyValue
97 Nd1fba539efd44c2c8d5be9cc7fb546ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Administration, Oral
99 rdf:type schema:DefinedTerm
100 Neb4cd6877ab34d3a8bef798aa70b3dbe schema:name nlm_unique_id
101 schema:value 0372741
102 rdf:type schema:PropertyValue
103 Nf06c8badfe5c479686843cd57bcd5ad7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Humans
105 rdf:type schema:DefinedTerm
106 Nf27e7797a8b0451ca2df3b6a417378dc rdf:first N0e7547bf84744d5882e4ef24d82ba30a
107 rdf:rest N10226d64e7754217ac1c32a3d471603a
108 Nfe1c19f5300f420da6d520d248870514 schema:name University of North Carolina Research Triangle Institute, Research Triangle Park, and School of Medicine Chapel Hill
109 rdf:type schema:Organization
110 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
111 schema:name Medical and Health Sciences
112 rdf:type schema:DefinedTerm
113 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
114 schema:name Pharmacology and Pharmaceutical Sciences
115 rdf:type schema:DefinedTerm
116 sg:journal.1017409 schema:issn 0009-9236
117 1532-6535
118 schema:name Clinical Pharmacology & Therapeutics
119 rdf:type schema:Periodical
120 sg:person.01053521033.24 schema:affiliation N4050d22b7db544a2b5fb58849f947c0e
121 schema:familyName Sadler
122 schema:givenName Brian M
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053521033.24
124 rdf:type schema:Person
125 sg:person.0107666412.52 schema:affiliation Nb853626a52504bbd8c89d9f931de3201
126 schema:familyName Wall
127 schema:givenName Monroe E
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0107666412.52
129 rdf:type schema:Person
130 sg:person.01255166721.72 schema:affiliation N0c73d23472424e34a080607d6c57f77d
131 schema:familyName Perez‐Reyes
132 schema:givenName Mario
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255166721.72
134 rdf:type schema:Person
135 sg:person.01305006065.32 schema:affiliation N7c0162bc950f45f987976848a6fb83e2
136 schema:familyName Brine
137 schema:givenName Dolores
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305006065.32
139 rdf:type schema:Person
 




Preview window. Press ESC to close (or click here)


...